ClinicalTrials.gg
Not yet recruitingNCT07525167Updated Jul 9, 2026

Early Prediction of Bronchopulmonary Dysplasia in Preterm Infants Using Clinical Data

An observational study in Bronchopulmonary Dysplasia, sponsored by Konya City Hospital. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 0 Days to 28 Days. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Konya City Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
108
Ages
0 Days to 28 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Bronchopulmonary Dysplasia with a site in Turkey — 2 open to participants now, 2 under way, none of them phase 3. Bronchopulmonary Dysplasia · Turkey.

Started
2026
the only one that year
Observational
5 of 13
2 open now
Registered
12th of 13
by date
Lead sponsor
1 of 13
Konya City Hospital

Among the 13 studies in Bronchopulmonary Dysplasia with a site in Turkey, this one is the only one that started in 2026, is one of 5 observational ones, and was the 12th registered.

Bronchopulmonary Dysplasia

363 studies on the registry are indexed under Bronchopulmonary Dysplasia; 85 are open to participants now.

Browse Bronchopulmonary Dysplasia studies →

Open to participants now

2 of the 13 studies in Bronchopulmonary Dysplasia with a site in Turkey are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 57 Bronchopulmonary Dysplasia studies recruiting now, 6 (11%) set no upper age limit and 50 (88%) stop at 75 or younger; 55 take children under 18; 11 take healthy volunteers.

This study: 0 Days to 28 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Bronchopulmonary Dysplasia with a site in Turkey, or all of them as a file.
02

Study summary

Early Prediction of Bronchopulmonary Dysplasia in Preterm Infants Using Clinical Data from the First Three Postnatal Weeks with Large Language Models: A Retrospective Study This retrospective, observational study aims to evaluate the early prediction of bronchopulmonary dysplasia (BPD) in preterm infants using clinical data from the first, second, and third postnatal weeks. The study includes infants born before 32 weeks of gestation or weighing less than 1,500 grams, followed at the Neonatal Intensive Care Unit of Konya City Hospital.

The study will compare the performance of different large language models (LLMs), including ChatGPT, Gemini, and Claude, in predicting BPD development. Clinical variables such as gestational age, birth weight, respiratory support, oxygen requirement, mechanical ventilation duration, and infection status will be used.

Primary outcome: Accuracy of BPD risk prediction by each AI model compared to actual clinical outcomes. Secondary outcomes: Sensitivity and specificity of predictions, weekly prediction performance, and comparative performance among AI models.

The results will provide insight into the potential clinical utility of AI-based approaches for early BPD risk assessment in preterm infants.

Read the detailed description

Premature birth remains a major risk factor for neonatal morbidity and mortality, with bronchopulmonary dysplasia (BPD) representing one of the most significant chronic pulmonary complications in very preterm infants. Despite advances in neonatal intensive care, early and accurate prediction of BPD remains challenging due to the multifactorial nature of its pathophysiology, involving respiratory support requirements, oxygen exposure, infection burden, and perinatal factors.

This retrospective study evaluates the feasibility of using large language models (LLMs) for early prediction of BPD based on structured clinical data extracted from neonatal intensive care unit (NICU) records. Clinical variables are organized into weekly datasets corresponding to the first, second, and third postnatal weeks to capture the dynamic evolution of respiratory status and clinical condition over time.

Standardized and anonymized patient-level datasets are formatted into structured prompts and provided to multiple LLMs (ChatGPT, Gemini, and Claude). Each model receives identical input variables to ensure comparability. The models are instructed to generate categorical risk stratification (low, medium, high) along with corresponding probability estimates for BPD development.

To ensure methodological consistency, prompt engineering is standardized across all models and time points. Outputs are recorded for each weekly time window, allowing temporal comparison of predictive performance and assessment of how early postnatal data influences model accuracy.

Model outputs are subsequently compared with confirmed clinical outcomes of BPD development in the study population. Performance evaluation focuses on discriminative ability and calibration of predictions across different time points and models.

This design enables a systematic assessment of the potential role of LLM-based approaches in neonatal risk stratification and provides insight into their applicability as supportive clinical decision-making tools in neonatal intensive care settings.

03

Conditions studied

  • Bronchopulmonary Dysplasia

Keywords

  • Bronchopulmonary Dysplasia
  • Machine Learning
  • Artificial Intelligence
  • preterm infant
04

Who can participate

Ages eligible
0 Days to 28 Days
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A retrospective cohort of preterm infants (\<32 weeks gestation or \<1,500 g) admitted to the NICU of Konya City Hospital. Only infants with complete clinical data and documented BPD status are included. Both sexes are included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Preterm infants born before 32 weeks of gestation or with birth weight \<1,500 grams
  • Admitted and followed in the Neonatal Intensive Care Unit (NICU) of Konya City Hospital
  • Availability of complete clinical data in hospital records
  • Documented bronchopulmonary dysplasia (BPD) outcome status

Exclusion criteria

Exclusion Criteria:

  • Presence of major congenital anomalies
  • Incomplete or missing clinical data
  • Death shortly after birth with insufficient follow-up data to determine BPD status
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
108 participants (estimated)
Target follow-up
3 Weeks
Patient registry
Yes

Groups and cohorts

  • Preterm Infants Cohort (<32 weeks or <1500 g)

    This cohort includes preterm infants born before 32 weeks of gestation or weighing less than 1,500 grams, followed at the Neonatal Intensive Care Unit of Konya City Hospital. Clinical data from the first, second, and third postnatal weeks are retrospectively collected for analysis. No interventions are applied; AI models are used to predict BPD risk based on existing clinical data.

    Other: Artificial Intelligence-Based Risk Prediction

Interventions

  • OtherArtificial Intelligence-Based Risk Prediction

    Different large language models (ChatGPT, Gemini, Claude) will analyze retrospective clinical data to predict the risk of bronchopulmonary dysplasia (BPD). This is an observational evaluation; no experimental treatment or therapy is administered.

06

What researchers measure

Primary outcomes

  1. Accuracy of bronchopulmonary dysplasia (BPD) risk prediction by artificial intelligence (AI) models in preterm infants.

    The primary outcome is the accuracy of different large language models (ChatGPT, Gemini, Claude) in predicting BPD development. AI-generated risk predictions will be compared to actual clinical outcomes to assess prediction correctness.

    Time frame: Postnatal weeks 1, 2, and 3

Secondary outcomes

  1. Sensitivity and specificity of AI predictions

    Evaluate the true positive rate (sensitivity) and true negative rate (specificity) of each AI model's BPD risk predictions compared to actual outcomes.

    Time frame: Postnatal weeks 1, 2, and 3

  2. Comparison of prediction accuracy across postnatal weeks

    Compare AI model performance at different postnatal weeks to determine if prediction accuracy improves as more clinical data becomes available.

    Time frame: Postnatal weeks 1, 2, and 3

  3. Comparative performance of different AI models

    Compare AI model performance at different postnatal weeks to determine if prediction accuracy improves as more clinical data becomes available.

    Time frame: Postnatal weeks 1, 2, and 3

07

Study locations

1 site
  • Konya City Hospital, İstiklal, Adana Çevre Yolu Cd. No:135/1
    Konya, 42020, Turkey (Türkiye)
08

References and documents

Publications

  • 1. Dai D, Chen H, Dong X, Chen J, Mei M, Lu Y, et al. Bronchopulmonary dysplasia predicted by developing a machine learning model of genetic and clinical information. Front Genet. 2021;12:689071. 2. Choi HJ, Lee G, Shin SH, Lee SM, Lee HC, Sohn JA, et al. Development and external validation of a machine learning model to predict bronchopulmonary dysplasia using dynamic factors. Sci Rep. 2025;15:13620. 3. Chen Y, Ma H, Liu X. Clinical and imaging data-based machine learning for early diagnosis of bronchopulmonary dysplasia: A meta-analysis. Curr Med Imaging. 2025;21:e15734056421036. 4. Özçelik G, Erol S, Korkut S, Köse Çetinkaya A, Özçelik H. Prediction of bronchopulmonary dysplasia using machine learning from chest X-rays of premature infants in the neonatal intensive care unit. Medicine (Baltimore).2025;104:e44322. 5. Akila K, Aravind Babu LR. Deep learning-driven early prediction of bronchopulmonary dysplasia using chest X-rays and clinical data. Electronics Communications and Computing Summit. 2025;3(3):90-97. 6. Zhang X, Wang Y, Li J, et al. Development and validation of machine learning models for predicting bronchopulmonary dysplasia risk in preterm neonates based on antenatal determinants. BMC Pediatr. 2025. 7. Li Y, Wang L, Chen Z, et al. Machine learning models combining oversampling techniques for prediction of bronchopulmonary dysplasia-associated pulmonary hypertension in very preterm infants. Respir Res. 2024;25:199.

Individual participant data

Plan to share: No — This study uses retrospective, de-identified clinical data from preterm infants admitted to the Neonatal Intensive Care Unit of Konya City Hospital. All patient information has been anonymized to protect privacy and confidentiality. Due to the sensitive nature of neonatal health data and institutional regulations, individual participant data (IPD) will not be shared with other researchers. The study results will be reported in aggregate form only, ensuring that no identifiable information is disclosed.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2026, 2 months later.

Of 47 non-industry observational studies under Bronchopulmonary Dysplasia, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 82. This study's planned 2 months is below that.

Counting every sponsor, half of 49 studies reached it within 56 months; a quarter within 19 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2026
First posted
Apr 13, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07525167
Lead sponsor
Konya City Hospital
Responsible party
Melek Buyukeren (Associate Professor, Department of Neonatology, Konya City Hospital, Konya City Hospital) — Principal investigator
First posted
Apr 13, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 9, 2026

Study contacts

Melek Büyükeren, Assoc. Prof. Dr.
Contact
melekbuyukeren@gmail.com
+90532-780-30-78

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion